Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants

Heba N. Altarawneh, MD,1,2,3 Hiam Chemaitelly, PhD1,2,3, Houssein H. Ayoub, PhD5, Mohammad R. Hasan, PhD4, Peter Coyle, MD6,7,8, Hadi M. Yassine, PhD7,9, Hebah A. Al-Khatib, PhD7,9, Fatiha M. Benslimane, PhD7,9, Zaina Al-Kanaani, PhD6, Einas Al-Kuwari, MD6, Andrew Jeremijenko, MD6, Anvar Hassan Kaleeckal, MSc6, Ali Nizar Latif, MD6, Riyazuddin Mohammad Shaik, MSc6, Hanan F. Abdul-Rahim, PhD10, Gheyath K. Nasrallah, PhD7,9, Mohamed Ghaith Al-Kuwari, MD11, Adeel A. Butt, MBBS MS3,6,12, Hamad Eid Al-Romaihi, MD13, Mohamed H. Al-Thani, MD13, Abdullatif Al-Khal, MD6, and Roberto Bertollini, MD MPH13, Patrick Tang, MD PhD4, and Laith J. Abu-Raddad, PhD1,2,3,10∗

1Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar
2World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
3Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA
4Department of Pathology, Sidra Medicine, Doha, Qatar
5Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar
6Hamad Medical Corporation, Doha, Qatar
7Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar
8Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom
9Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar
10Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
11Primary Health Care Corporation, Doha, Qatar
12Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York, USA
13Ministry of Public Health, Doha, Qatar

For correspondence: Professor Laith J. Abu-Raddad, E-mail: lja2002@qatar-med.cornell.edu.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

This study estimates the effectiveness of previous infection with SARS-CoV-2 in preventing reinfection with Omicron BA.4/BA.5 subvariants using a test-negative, case–control study design. Cases (SARS-CoV-2-positive test results) and controls (SARS-CoV-2-negative test results) were matched according to sex, 10-year age group, nationality, comorbid condition count, calendar week of testing, method of testing, and reason for testing. Effectiveness was estimated using the S-gene “target failure” (SGTF) infections between May 7, 2022-July 4, 2022. SGTF status provides a proxy for BA.4/BA.5 infections, considering the negligible incidence of other SGTF variants during the study. Effectiveness was also estimated using all diagnosed infections between June 8, 2022-July 4, 2022, when BA.4/BA.5 dominated incidence. Effectiveness of a previous pre-Omicron infection against symptomatic BA.4/BA.5 reinfection was 15.1% (95% CI: -47.1-50.9%), and against any BA.4/BA.5 reinfection irrespective of symptoms was 28.3% (95% CI: 11.4-41.9%). Effectiveness of a previous Omicron infection against symptomatic BA.4/BA.5 reinfection was 76.1% (95% CI: 54.9-87.3%), and against any BA.4/BA.5 reinfection was 79.7% (95% CI: 74.3-83.9%). Results using all diagnosed infections when BA.4/BA.5 dominated incidence confirmed the same findings. Sensitivity analyses adjusting for vaccination status confirmed study results. Protection of a previous infection against BA.4/BA.5 reinfection was modest when the previous infection involved a pre-Omicron variant, but strong when the previous infection involved the Omicron BA.1 or BA.2 subvariants. Protection of a previous infection against BA.4/BA.5 was lower than that against BA.1/BA.2, consistent with BA.4/BA.5’s greater capacity for immune-system evasion than that of BA.1/BA.2.
Introduction

Omicron BA.4 and BA.5 (B.1.1.529) subvariants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged in recent weeks and exhibit substantial capacity to escape from neutralizing antibodies. These subvariants were introduced in Qatar by early May of 2022 (Figure 1), and became the dominant subvariants by June 8, 2022 (Figure 2). We estimated effectiveness of previous infection in preventing reinfection with BA.4/BA.5 using a test-negative, case–control study design.

Methods

Study population, data sources, and study design

This study was conducted in the resident population of Qatar, applying the test-negative, case-control study design to investigate the protection afforded by previous SARS-CoV-2 infection in preventing reinfection with SARS-CoV-2 BA.4 or BA.5 Omicron subvariants. Effectiveness of previous infection in preventing reinfection \( (PE) \) was defined as the proportional reduction in susceptibility to infection among those with previous infection versus those without. The test-negative methodology was recently developed and validated for the specific derivation of rigorous and robust estimates for SARS-CoV-2 \( PE \), and has been applied in other recent studies for this purpose.

The study analyzed the national, federated databases for coronavirus disease 2019 (COVID-19) laboratory testing, vaccination, clinical infection data, hospitalization, and death, retrieved from the integrated nationwide digital-health information platform. Databases include all SARS-CoV-2-related data and associated demographic information, with no missing information, since
pandemic onset, documenting all polymerase chain reaction (PCR) testing and more recently, rapid antigen (RA) testing conducted at healthcare facilities (from January 5, 2022 onward).

Every PCR test (but not every RA test) conducted in Qatar is classified on the basis of symptoms and the reason for testing (clinical symptoms, contact tracing, surveys or random testing campaigns, individual requests, routine healthcare testing, pre-travel, at port of entry, or other). PCR and RA testing in Qatar is done at a mass scale, where about 5% of the population are tested every week. Most infections are diagnosed not because of appearance of symptoms, but because of routine testing. Qatar has unusually young, diverse demographics, in that only 9% of its residents are ≥50 years of age, and 89% are expatriates from over 150 countries. Qatar launched its COVID-19 vaccination program in December of 2020 using BNT162b2 and mRNA-1273 vaccines. Further descriptions of the study population and these national databases have been reported previously.

For estimation of $PE_S$ against BA.4 or BA.5 infection, we exact-matched cases (SARS-CoV-2-positive tests) and controls (SARS-CoV-2-negative tests) in a one-to-five ratio by sex, 10-year age group, nationality, comorbid condition count, calendar week of testing, method of testing (PCR or RA), and reason for testing. Matching was done to control for known differences in risk of exposure to SARS-CoV-2 infection in Qatar. Matching by these factors was previously shown to provide adequate control of differences in risk of SARS-CoV-2 exposure in studies of different designs and that included control groups to test for null effects, including test-negative case-control studies.

Effectiveness was estimated using two sets of cases. The first one includes the S-gene “target failure” (SGTF) cases identified using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA). Routine PCR mass testing was designed to allow capture of SGTF variants
during the study. SGTF status provides a proxy for BA.4 or BA.5 cases, considering the limited incidence of other variants with SGTF in Qatar during the study, between May 7, 2022 and July 4, 2022. To improve on statistical precision, an additional estimate was generated using all cases diagnosed when BA.4 and BA.5 dominated incidence, that is between June 8, 2022 and July 4, 2022. This estimate provides an upper bound for the effectiveness considering that some infections during this time could have been with BA.2, a subvariant associated with less immune evasion compared to BA.4 and BA.5.1,8

Only the first SARS-CoV-2-positive test for an individual occurring during the study period was included, while all SARS-CoV-2-negative tests were included. Controls included SARS-CoV-2-negative tests on individuals with no record of a SARS-CoV-2-positive test during the study.

SARS-CoV-2 reinfection is conventionally defined as a documented infection ≥90 days after an earlier infection, to avoid misclassification of prolonged PCR positivity as reinfection, if a shorter time interval is used.8,25 Previous infection was thus defined as a SARS-CoV-2-positive test ≥90 days before this study’s SARS-CoV-2 test. Cases or controls with SARS-CoV-2-positive tests <90 days before the study’s SARS-CoV-2 test were excluded.

Every control that met the inclusion criteria and that could be matched to a case was included in analysis. The above inclusion and exclusion criteria were implemented to minimize different types of potential bias, as informed by previous analyses.7,8,10 Previous infections were classified as pre-Omicron versus Omicron previous infections based on whether they occurred before or after the Omicron wave that started in Qatar on December 19, 2021.7,8,17
Laboratory methods

Real-time reverse-transcription polymerase chain reaction testing

Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: 1) extracted on KingFisher Flex (Thermo Fisher Scientific, USA), MGISP-960 (MGI, China), or ExiPrep 96 Lite (Bioneer, South Korea) followed by testing with real-time reverse-transcription PCR (RT-qPCR) using TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on an ABI 7500 FAST (Thermo Fisher Scientific, USA); 2) tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or 3) loaded directly into a Roche cobas 6800 system and assayed with the cobas SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or Sidra Medicine Laboratory, following standardized protocols.

Rapid antigen testing

SARS-CoV-2 antigen tests were performed on nasopharyngeal swabs using one of the following lateral flow antigen tests: Panbio COVID-19 Ag Rapid Test Device (Abbott, USA); SARS-CoV-2 Rapid Antigen Test (Roche, Switzerland); Standard Q COVID-19 Antigen Test (SD Biosensor, Korea); or CareStart COVID-19 Antigen Test (Access Bio, USA). All antigen tests were performed point-of-care according to each manufacturer’s instructions at public or private hospitals and clinics throughout Qatar with prior authorization and training by the Ministry of Public Health (MOPH). Antigen test results were electronically reported to the MOPH in real
time using the Antigen Test Management System which is integrated with the national COVID-19 database.

**Viral genome sequencing and classification of infections by variant type**

Surveillance for SARS-CoV-2 variants in Qatar is based on viral genome sequencing and multiplex RT-qPCR variant screening\(^\text{26}\) of random positive clinical samples,\(^\text{10,15,16,27-29}\) complemented by deep sequencing of wastewater samples.\(^\text{27,30}\) Further details on the viral genome sequencing and multiplex RT-qPCR variant screening throughout the SARS-CoV-2 waves in Qatar can be found in previous publications.\(^\text{7,8,10,15-17,27-29,31-33}\)

A total of 82 random SARS-CoV-2-positive specimens collected between May 28, 2022 and June 10, 2022 were viral whole-genome sequenced on a Nanopore GridION sequencing device. Of these, 1 (1.2%) was confirmed as Omicron BA.1, 38 (46.3%) as BA.2, 9 (11.0%) as BA.4, and 34 (41.5%) as BA.5.

Moreover, between June 5, 2022 and June 25, 2022, whole-genome sequencing of an additional 93 random SARS-CoV-2-positive specimens with PCR cycle threshold (Ct) values ≤25 showed 63 (67.7%) were BA.5, 7 (7.5%) were BA.4, 19 (20.4%) were BA.2, and 4 (4.3%) were BA.1.

Additionally, between May 1, 2022 and June 15, 2022, S-gene sequencing of 84 other random SARS-CoV-2-positive specimens with SGTF showed 81 (96.4%) were BA.4/BA.5 and 3 (3.6%) were BA.1.

**Statistical analysis**

While all records of SARS-CoV-2 testing were examined for selection of cases and controls, only matched samples were analyzed. Cases and controls were described using frequency distributions and measures of central tendency and compared using standardized mean
differences. A standardized mean difference was defined as the difference in the mean of a
covariate between groups, divided by the pooled standard deviation, with values <0.1 indicating
optimal matching.⁴

\[ P_{ES} \] was derived as one minus the ratio of the odds of previous infection in cases (SARS-CoV-2-
positive tests), to the odds of previous infection in controls (SARS-CoV-2-negative tests):²

\[ P_{ES} = 1 − \text{odds ratio of prior infection among cases versus controls} \]

Odds ratios and associated 95% confidence intervals (CIs) were derived using conditional
logistic regression, factoring the matching in the study design. This analytical approach, that also
factors matching by calendar week of test, minimizes potential bias due to variation in epidemic
phase³,⁵ and roll-out of vaccination during the study.³,⁵ CIs were not adjusted for multiplicity
and thus should not be used to infer definitive differences between different groups. Interactions
were not investigated.

Sensitivity analyses were conducted to assess the robustness of estimates of \( P_{ES} \). This was done
by additionally adjusting for vaccination status in the conditional logistic regression. Statistical
analyses were conducted in STATA/SE version 17.0 (Stata Corporation, College Station, TX,
USA).

**Oversight**

Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards
approved this retrospective study with a waiver of informed consent. The study was reported
following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guidelines. The STROBE checklist is found in Table 1.

**Results**
Figures 3-4 show selection of the study population and Table 2 shows the population’s baseline characteristics. The study population was broadly representative of Qatar’s population.

Effectiveness of a previous pre-Omicron infection against symptomatic BA.4/BA.5 reinfection was 15.1% (95% CI: -47.1-50.9%), and against any BA.4/BA.5 reinfection irrespective of symptoms was 28.3% (95% CI: 11.4-41.9%) (Table 3). Effectiveness of a previous Omicron infection against symptomatic BA.4/BA.5 reinfection was 76.1% (95% CI: 54.9-87.3%), and against any BA.4/BA.5 reinfection was 79.7% (95% CI: 74.3-83.9%).

Results using all diagnosed infections when BA.4/BA.5 dominated incidence showed higher effectiveness estimates, as expected for an upper bound, but still confirmed the same findings with improved statistical precision (Table 3). Sensitivity analyses adjusting for vaccination status confirmed study results (Table 3).

**Discussion**

Protection of a previous infection against BA.4/BA.5 reinfection was modest when the previous infection involved a pre-Omicron variant, but strong when the previous infection involved the Omicron BA.1 or BA.2 subvariant. Importantly, protection of a previous infection against BA.4/BA.5 was lower than that against BA.1/BA.2,7,8,36 consistent with BA.4/BA.5’s greater capacity for immune-system evasion than that of BA.1/BA.2.

**Limitations**

With the young population of Qatar, our findings may not be generalizable to other countries where elderly citizens constitute a larger proportion of the total population. With the relatively young population of Qatar,12,37 the lower severity of Omicron,38-40 and the time lag between infection and severe forms of COVID-19, there were too small number of confirmed severe,41
critical,\textsuperscript{41} and fatal\textsuperscript{42} COVID-19 cases to estimate \textit{PES} against COVID-19 hospitalization and death due to reinfection. Because also of the relatively small number of infections, it was not possible to generate effectiveness estimates by time since previous infection.

The study is based on SARS-CoV-2 tests done on individuals currently in Qatar. Qatar has a diverse expatriate population, and it is possible that some persons may have had a previous infection diagnosis while traveling abroad to visit family or for vacation, but which would not have been captured in our national databases. However, this is not likely to affect our estimates. It has already been shown that even considerable levels of misclassification of previous infection status had a minimal impact on estimated \textit{PES},\textsuperscript{2} a key strength of the test-negative design.\textsuperscript{2}

While matching was done for sex, 10-year age group, nationality, comorbid condition count, calendar week of testing, method of testing (PCR or RA), and reason for testing, this was not possible for other factors such as geography or occupation, as such data were unavailable. However, Qatar is essentially a city state and infection incidence was broadly distributed across neighborhoods. Nearly 90\% of Qatar’s population are expatriates from over 150 countries coming here because of employment;\textsuperscript{12} most are craft and manual workers working in development projects.\textsuperscript{12} Nationality, age, and sex provide a powerful proxy for socio-economic status in this country.\textsuperscript{12,18-21} Nationality alone is strongly associated with occupation.\textsuperscript{12,18-21}

Matching was done to control for factors known to affect infection exposure in Qatar.\textsuperscript{12,18-21} The matching prescription had already been investigated in previous studies of different epidemiologic designs, and using control groups to test for null effects.\textsuperscript{10,13,16,22,23} These control groups included unvaccinated cohorts versus vaccinated cohorts within two weeks of the first dose,\textsuperscript{10,16,22,23} when vaccine protection is negligible,\textsuperscript{43,44} and mRNA-1273- versus BNT162b2-vaccinated cohorts, also in the first two weeks after the first dose.\textsuperscript{13} These studies have shown
that this prescription provides adequate control of the differences in infection exposure.\textsuperscript{10,13,16,22,23} The study was implemented on Qatar’s total population, perhaps thus minimizing the likelihood of bias.

$PE_S$ was assessed using an observational, test-negative, case-control study design,\textsuperscript{2} rather than a cohort study design where individuals are followed up over time. However, the cohort study design applied in earlier analyses to estimate $PE_S$ in the same population of Qatar yielded findings similar to those of the test-negative, case-control study design,\textsuperscript{2,6,14,45,46} supporting the validity of this design in estimating $PE_S$. It even appears that the test-negative study design may be less prone to some forms of bias than the cohort study design.\textsuperscript{2}

Nonetheless, one cannot exclude the possibility that in real-world data, bias could arise in unexpected ways, or from unknown sources, such as subtle differences in test-seeking behavior or changes in the pattern of testing. Notwithstanding these limitations, consistent findings were reached in all the different primary and sensitivity analyses.
References


Acknowledgements

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, the Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine – Qatar for their diligent efforts and contributions to make this study possible.

The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. Statements made herein are solely the responsibility of the authors. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.

Author contributions

HNA co-designed the study, performed the main statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, performed statistical analyses, and co-wrote the first draft of the article. PVC designed mass PCR testing to allow routine capture of SGTF variants. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HY, HAK, and MKS conducted viral genome sequencing. HA contributed to study design. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.
Competing interests

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise we declare no competing interests.

Funding

This work was supported by the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar; the Qatar Ministry of Public Health; Hamad Medical Corporation; and Sidra Medicine. The Qatar Genome Program and Qatar University Biomedical Research Center supported viral genome sequencing.
Figure 1. Proportion of SARS-CoV-2 Omicron infections that are with the BA.4 or BA.5 subvariants versus with the BA.2 subvariant, the only other subvariant of appreciable presence in Qatar between May 1, 2022 and July 3, 2022. BA.4 or BA.5 subvariant status was proxied as an S-gene “target failure” (SGTF) status in the PCR testing conducted using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA)24.
Figure 2. Daily number of newly diagnosed SARS-CoV-2 infections between May 1, 2022 and July 3, 2022.
<table>
<thead>
<tr>
<th>Item No</th>
<th>Title and abstract</th>
<th>Recommendation</th>
<th>Main text page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(a) Indicate the study’s design with a commonly used term in the title or the abstract.</td>
<td></td>
<td>Abstract</td>
</tr>
<tr>
<td></td>
<td>(b) Provide in the abstract an informative and balanced summary of what was done and what was found.</td>
<td></td>
<td>Abstract</td>
</tr>
<tr>
<td>2</td>
<td>Explain the scientific background and rationale for the investigation being reported.</td>
<td></td>
<td>Introduction</td>
</tr>
<tr>
<td>3</td>
<td>State specific objectives, including any prespecified hypotheses.</td>
<td></td>
<td>Introduction</td>
</tr>
</tbody>
</table>

**Methods**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Description</th>
<th>Main text page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Present key elements of study design</td>
<td>Methods ('Study population, data sources, and study design')</td>
</tr>
<tr>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</td>
<td>Methods ('Study population, data sources, and study design')</td>
</tr>
<tr>
<td>6</td>
<td>(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</td>
<td>Methods ('Study population, data sources, and study design', 'Laboratory methods'), &amp; Figures 3 &amp; 4</td>
</tr>
<tr>
<td></td>
<td>(b) For matched studies, give matching criteria and the number of controls per case</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</td>
<td>Methods ('Study population, data sources, and study design', 'Laboratory methods', 'Statistical analysis')</td>
</tr>
<tr>
<td>8</td>
<td>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</td>
<td>Methods ('Study population, data sources, and study design', 'Laboratory methods', 'Statistical analysis') &amp; Table 2</td>
</tr>
<tr>
<td>9</td>
<td>Describe any efforts to address potential sources of bias</td>
<td>Methods ('Study population, data sources, and study design') &amp; Figures 3 &amp; 4</td>
</tr>
<tr>
<td>10</td>
<td>Explain how the study size was arrived at</td>
<td>Methods ('Study population, data sources, and study design') &amp; Figures 3 &amp; 4</td>
</tr>
<tr>
<td>11</td>
<td>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</td>
<td>Methods ('Study population, data sources, and study design') &amp; 'Statistical analysis' &amp; Table 2</td>
</tr>
<tr>
<td>12</td>
<td>(a) Describe all statistical methods, including those used to control for confounding</td>
<td>Methods ('Statistical analysis')</td>
</tr>
<tr>
<td></td>
<td>(b) Describe any methods used to examine subgroups and interactions</td>
<td>Methods ('Statistical analysis'), &amp; Table 3</td>
</tr>
<tr>
<td></td>
<td>(c) Explain how missing data were addressed</td>
<td>NA, see Methods ('Study population, data sources, and study design')</td>
</tr>
<tr>
<td></td>
<td>(d) If applicable, explain how matching of cases and controls was addressed</td>
<td>Methods ('Study population, data sources, and study design')</td>
</tr>
<tr>
<td></td>
<td>(e) Describe any sensitivity analyses</td>
<td>Methods ('Statistical analysis'), &amp; Table 3</td>
</tr>
</tbody>
</table>

**Results**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Description</th>
<th>Main text page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</td>
<td>Figures 3 &amp; 4</td>
</tr>
<tr>
<td></td>
<td>(b) Give reasons for non-participation at each stage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(c) Consider use of a flow diagram</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</td>
<td>Table 2</td>
</tr>
<tr>
<td></td>
<td>(b) Indicate number of participants with missing data for each variable of interest</td>
<td>NA, see Methods ('Study population, data sources, and study design')</td>
</tr>
<tr>
<td>15</td>
<td>Report numbers in each exposure category, or summary measures of exposure</td>
<td>Results &amp; Table 3</td>
</tr>
<tr>
<td>16</td>
<td>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</td>
<td>Results &amp; Table 3</td>
</tr>
<tr>
<td></td>
<td>(b) Report category boundaries when continuous variables were categorized</td>
<td>Methods ('Study population, data sources, and study design')</td>
</tr>
<tr>
<td>Other analyses</td>
<td>17</td>
<td>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</td>
</tr>
<tr>
<td>----------------</td>
<td>----</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key results</td>
<td>18</td>
<td>Summarise key results with reference to study objectives</td>
</tr>
<tr>
<td>Limitations</td>
<td>19</td>
<td>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</td>
</tr>
<tr>
<td>Interpretation</td>
<td>20</td>
<td>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence</td>
</tr>
<tr>
<td>Generalisability</td>
<td>21</td>
<td>Discuss the generalisability (external validity) of the study results</td>
</tr>
<tr>
<td><strong>Other information</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>22</td>
<td>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</td>
</tr>
</tbody>
</table>

NA denotes not applicable.
Figure 3. Flowchart describing the population selection process for investigating effectiveness of previous infection in preventing reinfection with the BA.4 or BA.5 subvariants using the S-gene “target failure” diagnosed infections, May 7, 2022-July 4, 2022.

6,859 Individuals with a first PCR-positive SARS-CoV-2 infection between May 7-July 4, 2022 (end of study)

702 Individuals were excluded because of non-SGIT status in the PCR test

4,091 Individuals were excluded because they were not tested using the TaqPath COVID-19 Combo Kit

176 Individuals were excluded because they had a record for a prior infection within 90 days of the study PCR-positive test

1,619 Individuals were excluded because they were not tested for clinical suspicion

271 PCR-positive SARS-CoV-2 tests with BA.4 or BA.5 Omicron infection for 271 individuals who were tested for clinical suspicion

1,890 PCR-positive SARS-CoV-2 tests with BA.4 or BA.5 Omicron infection for 1,890 individuals

73 Tests not matched

411 Tests not matched

1,479 PCR-positive tests for 1,479 individuals with BA.4 or BA.5 Omicron infection matched1 to PCR-negative SARS-CoV-2 tests

155,476 Individuals with 174,265 PCR-negative SARS-CoV-2 tests between May 7-July 4, 2022 (end of study)

665 Individuals were excluded because they had a record for a prior infection within 90 days of the study PCR-negative test

141,534 Individuals were excluded because they were not tested for clinical suspicion

14,851 PCR-negative SARS-CoV-2 tests for 13,277 individuals who were tested for clinical suspicion

173,476 PCR-negative SARS-CoV-2 tests for 154,811 individuals

14,109 PCR-negative tests not matched

167,324 PCR-negative tests not matched

742 PCR-negative tests for 698 individuals matched2 to individuals with symptomatic BA.4 or BA.5 Omicron infection

6,152 PCR-negative tests for 6,038 individuals matched2 to individuals with BA.4 or BA.5 Omicron infection

1PCR denotes polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, and SGIT S-gene “target failure”.

2Testing for clinical suspicion is defined as a SARS-CoV-2 PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

1Individuals with a PCR-positive SARS-CoV-2 test were exact-matched one-to-five by sex, 10-year age group, nationality, comorbid condition count, and calendar week of PCR test to first eligible PCR-negative SARS-CoV-2 test.

2Individuals with a PCR-positive SARS-CoV-2 test were exact-matched one-to-five by sex, 10-year age group, nationality, comorbid condition count, calendar week of PCR test, and reason for testing to first eligible PCR-negative SARS-CoV-2 test.
Figure 4. Flowchart describing the population selection process for investigating effectiveness of previous infection in preventing reinfection with the BA.4 or BA.5 subvariants using all SARS-CoV-2 infections diagnosed when BA.4 and BA.5 dominated incidence, June 8, 2022-July 4, 2022.

15,736 Individuals with a first PCR-positive or RA-positive SARS-CoV-2 infection between June 8-July 4, 2022 (end of study)

348 Individuals were excluded because they had a record for a prior infection within 90 days of the study PCR-positive or RA-positive test

6,775 Individuals were excluded because they were not tested for clinical suspicion

2,184 PCR-positive or RA-positive SARS-CoV-2 tests with BA.4 or BA.5 Omicron infection for 2,184 individuals who were tested for clinical suspicion

8,959 PCR-positive or RA-positive SARS-CoV-2 tests with BA.4 or BA.5 Omicron infection for 8,959 individuals

4,545 PCR-negative or RA-negative tests for 4,328 individuals matched to individuals with symptomatic BA.4 or BA.5 Omicron infection

6,500 PCR-positive or RA-positive SARS-CoV-2 tests for 6,500 individuals with a BA.4 or BA.5 Omicron infection matched to PCR-negative or RA-negative SARS-CoV-2 tests

2,459 Tests not matched

952 Tests not matched

1,232 PCR-positive or RA-positive SARS-CoV-2 tests for 1,232 individuals with a symptomatic BA.4 or BA.5 Omicron infection matched to PCR-negative or RA-negative SARS-CoV-2 tests

301,452 Individuals with 338,849 PCR-negative or RA-negative SARS-CoV-2 tests between June 8-July 4, 2022 (end of study)

2,896 Individuals were excluded because they had a record for a prior infection within 90 days of the study PCR-negative or RA-negative test

177,417 Individuals were excluded because they were not tested for clinical suspicion

12,290 PCR-negative or RA-negative SARS-CoV-2 tests for 11,316 individuals who were tested for clinical suspicion

109,823 Individuals were excluded because the RA test reason for testing was not available

126,304 PCR-negative or RA-negative SARS-CoV-2 tests for 188,733 individuals

4,545 PCR-negative or RA-negative tests for 26,251 individuals matched to individuals with BA.4 or BA.5 Omicron infection

7,745 PCR-negative or RA-negative tests not matched

27,453 PCR-negative or RA-negative tests not matched

179,263 PCR-negative or RA-negative tests not matched

6,500 PCR-positive or RA-positive SARS-CoV-2 tests for 6,500 individuals with a BA.4 or BA.5 Omicron infection matched to PCR-negative or RA-negative SARS-CoV-2 tests

2,459 Tests not matched

952 Tests not matched

1,232 PCR-positive or RA-positive SARS-CoV-2 tests for 1,232 individuals with a symptomatic BA.4 or BA.5 Omicron infection matched to PCR-negative or RA-negative SARS-CoV-2 tests

2,896 Individuals were excluded because they had a record for a prior infection within 90 days of the study PCR-negative or RA-negative test

177,417 Individuals were excluded because they were not tested for clinical suspicion

8,959 PCR-positive or RA-positive SARS-CoV-2 tests with BA.4 or BA.5 Omicron infection for 8,959 individuals

4,545 PCR-negative or RA-negative tests for 4,328 individuals matched to individuals with symptomatic BA.4 or BA.5 Omicron infection

6,500 PCR-positive or RA-positive SARS-CoV-2 tests for 6,500 individuals with a BA.4 or BA.5 Omicron infection matched to PCR-negative or RA-negative SARS-CoV-2 tests

2,459 Tests not matched

952 Tests not matched

1,232 PCR-positive or RA-positive SARS-CoV-2 tests for 1,232 individuals with a symptomatic BA.4 or BA.5 Omicron infection matched to PCR-negative or RA-negative SARS-CoV-2 tests

PCR denotes polymerase chain reaction, RA rapid antigen, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.

*Testing for clinical suspicion is defined as a SARS-CoV-2 PCR-positive or RA-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

*Individuals with a PCR-positive or RA-positive SARS-CoV-2 test were exact-matched one-to-five by sex, 10-year age group, nationality, comorbid condition count, calendar week of SARS-CoV-2 test, and method of testing (PCR or RA) to first eligible SARS-CoV-2-negative test.

*Individuals with a PCR-positive or RA-positive SARS-CoV-2 test were exact-matched one-to-five by sex, 10-year age group, nationality, comorbid condition count, calendar week of SARS-CoV-2 test, method of testing (PCR or RA), and reason for testing to first eligible SARS-CoV-2-negative test.
Table 2. Characteristics of matched cases (SARS-CoV-2-positive tests) and controls (SARS-CoV-2-negative tests) in the analysis assessing effectiveness against symptomatic BA.4 or BA.5 reinfection and in the analysis assessing effectiveness against any BA.4 or BA.5 reinfection regardless of symptoms. The table is generated for the analyses including the S-gene “target failure” infections diagnosed between May 7, 2022 and July 4, 2022, and the analyses including all SARS-CoV-2 infections diagnosed between June 8, 2022 and July 4, 2022, when BA.4 and BA.5 dominated incidence.

<table>
<thead>
<tr>
<th>Study period</th>
<th>May 7, 2022-July 4, 2022</th>
<th>June 8, 2022-July 4, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
<td>Effectiveness against symptomatic BA.4 or BA.5 infection^*</td>
<td>Effectiveness against any BA.4 or BA.5 infection^†</td>
</tr>
<tr>
<td></td>
<td>Cases^1 (SGTF infections)</td>
<td>Controls^1 (Negative tests) SMD‡</td>
</tr>
<tr>
<td></td>
<td>N= 198</td>
<td>N= 742</td>
</tr>
<tr>
<td></td>
<td>N=6,500</td>
<td>N= 27,051</td>
</tr>
<tr>
<td>Median age (IQR) —years</td>
<td>36 (29-51)</td>
<td>35 (29-46)</td>
</tr>
<tr>
<td>Age group —n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10 years</td>
<td>7 (3.5)</td>
<td>31 (4.2)</td>
</tr>
<tr>
<td>10-19 years</td>
<td>7 (3.5)</td>
<td>15 (2.0)</td>
</tr>
<tr>
<td>20-29 years</td>
<td>39 (19.7)</td>
<td>161 (21.7)</td>
</tr>
<tr>
<td>30-39 years</td>
<td>59 (29.8)</td>
<td>264 (35.6)</td>
</tr>
<tr>
<td>40-49 years</td>
<td>30 (15.2)</td>
<td>108 (14.6)</td>
</tr>
<tr>
<td>50-59 years</td>
<td>32 (16.2)</td>
<td>90 (12.1)</td>
</tr>
<tr>
<td>60-69 years</td>
<td>16 (8.1)</td>
<td>45 (6.1)</td>
</tr>
<tr>
<td>70+ years</td>
<td>8 (4.0)</td>
<td>28 (3.8)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>88 (44.4)</td>
<td>326 (43.9)</td>
</tr>
<tr>
<td>Female</td>
<td>110 (55.6)</td>
<td>416 (56.1)</td>
</tr>
<tr>
<td>Nationality¶</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bangladeshi</td>
<td>4 (2.0)</td>
<td>15 (2.0)</td>
</tr>
<tr>
<td>Egyptian</td>
<td>1 (0.5)</td>
<td>3 (0.4)</td>
</tr>
<tr>
<td>Filipino</td>
<td>40 (20.2)</td>
<td>179 (24.1)</td>
</tr>
<tr>
<td>Indian</td>
<td>29 (14.6)</td>
<td>119 (16.0)</td>
</tr>
<tr>
<td>Nepalese</td>
<td>7 (3.5)</td>
<td>31 (4.2)</td>
</tr>
<tr>
<td>Pakistani</td>
<td>7 (3.5)</td>
<td>27 (3.6)</td>
</tr>
<tr>
<td>Qatari</td>
<td>65 (32.8)</td>
<td>217 (29.2)</td>
</tr>
<tr>
<td>Sri Lankan</td>
<td>2 (1.0)</td>
<td>10 (1.3)</td>
</tr>
<tr>
<td>Sudanese</td>
<td>2 (1.0)</td>
<td>10 (1.3)</td>
</tr>
<tr>
<td>Other nationalities</td>
<td>41 (20.7)</td>
<td>131 (17.7)</td>
</tr>
<tr>
<td>Comorbid condition count</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>138 (69.7)</td>
<td>577 (77.8)</td>
</tr>
<tr>
<td>1</td>
<td>20 (10.1)</td>
<td>53 (7.1)</td>
</tr>
<tr>
<td>2</td>
<td>9 (4.5)</td>
<td>26 (3.5)</td>
</tr>
<tr>
<td>3 or more</td>
<td>31 (15.7)</td>
<td>96 (12.9)</td>
</tr>
</tbody>
</table>

IQR denotes interquartile range, PCR polymerase chain reaction, RA rapid antigen, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, and SGTF S-gene “target failure”.

^*A symptomatic infection was defined as a SARS-CoV-2 PCR or RA test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

^†Cases and controls were exact matched one-to-five by sex, 10-year age group, nationality, comorbid condition count, calendar week of test, method of testing (PCR or RA), and reason for testing.

‡SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD <0.1 indicates adequate balance in matching.

§SMD is for the mean difference between groups divided by the pooled standard deviation.

All rights reserved. No reuse allowed without permission.
Nationalities were chosen to represent the most populous groups in Qatar.
Table 3. Effectiveness of previous SARS-CoV-2 infection in preventing reinfection with the Omicron BA.4 or BA.5 subvariants using A) S-gene “target failure” infections diagnosed between May 7, 2022 and July 4, 2022, and B) all SARS-CoV-2 infections diagnosed between June 8, 2022 and July 4, 2022, when BA.4 and BA.5 dominated incidence.

<table>
<thead>
<tr>
<th>Type of analysis</th>
<th>Cases' (SARS-CoV-2-positive tests)</th>
<th>Controls' (SARS-CoV-2-negative tests)</th>
<th>Effectiveness in % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median interval between previous infection and SARS-CoV-2 test (IQR) in days</td>
<td>Median interval between previous infection and SARS-CoV-2 test (IQR) in days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Previous infection (n)</td>
<td>No previous infection (n)</td>
<td>Previous infection (n)</td>
</tr>
<tr>
<td>A) Analysis using SGTF status as a proxy for BA.4 or BA.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-omicron previous infection</td>
<td>542 (455-713)</td>
<td>21</td>
<td>164</td>
</tr>
<tr>
<td>Omicron previous infection</td>
<td>169 (166-175)</td>
<td>13</td>
<td>164</td>
</tr>
<tr>
<td>B) Analysis using any infection during BA.4 and BA.5 dominance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-omicron previous infection</td>
<td>473 (427-628)</td>
<td>125</td>
<td>1,267</td>
</tr>
<tr>
<td>Omicron previous infection</td>
<td>166 (154-173)</td>
<td>87</td>
<td>1,267</td>
</tr>
<tr>
<td>Sensitivity analyses adjusting for vaccination status in conditional logistic regression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A) Analysis using SGTF as a proxy for BA.4 or BA.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-omicron previous infection</td>
<td>490 (438-685)</td>
<td>107</td>
<td>1,080</td>
</tr>
<tr>
<td>Omicron previous infection</td>
<td>167 (161-171)</td>
<td>45</td>
<td>1,080</td>
</tr>
<tr>
<td>B) Analysis using any infection during BA.4 and BA.5 dominance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-omicron previous infection</td>
<td>480 (435-647.5)</td>
<td>528</td>
<td>5,683</td>
</tr>
<tr>
<td>Omicron previous infection</td>
<td>167 (154-174)</td>
<td>289</td>
<td>5,683</td>
</tr>
</tbody>
</table>

CI denotes confidence interval, IQR interquartile range, PCR polymerase chain reaction, RA rapid antigen, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, and SGTF S-gene “target failure”.

*A symptomatic infection was defined as a SARS-CoV-2 PCR or RA test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

†Cases and controls were exact matched one-to-five by sex, 10-year age group, nationality, comorbid condition count, calendar week of test, method of testing (PCR or RA), and reason for testing.

‡Effectiveness of previous infection in preventing reinfection was estimated using the test-negative, case–control study design.²